To evaluate the efficacy and risks of complications of topical mitomycin C (MMC) for small-size conjunctival intraepithelial neoplasia (CIN).
Eight patients with clinically diagnosed CIN <8 mm were included in the study. Patients received topical drops of MMC, 0.02–0.04%, 4 times daily for 14 days. Retreatment was done when lesions were not eliminated or recurred after the first treatment.
Three patients remained disease free after one course of MMC application. Retreatment was done in four patients because of lesions that decreased in size but were not eliminated, and for regrowth in one case. After retreatment, the lesions were eradicated in four patients, whereas in one patient, the treatment failed, and the lesion was surgically excised. The complications of MMC use included mild conjunctival hyperemia in two patients and mild allergy in one patient, which resolved after discontinuation of the treatment.
Application of topical MMC is an effective treatment for most but not all cases of small-size CIN.
From the Departments of Ophthalmology, Shaarei-Zedek Medical Center (Y.R.), and Hadassah University Hospital (J.F.-P.), Jerusalem, Israel.
Submitted August 29, 1998.
Revision received May 12, 1999.
Accepted May 17, 1999.
Address correspondence and reprint requests to Dr. Y. Rozenman, Department of Ophthalmology, Shaare-Zedek Medical Center, P.0. Box 3235, Jerusalem, Israel.
Each author states that he has no proprietary interest in the development or marketing of this or a competing drug.